Abiopharma

Forgent Power Solutions Announces Pricing of Public Offering of Class A Common Stock

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

SSR Mining Announces Normal Course Issuer Bid

Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

Vertical Aerospace Selects Isoclima as Strategic Transparency Partner for Valo

Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD